Ameriprise’s Astera Labs ALAB Stock Holding History

Ameriprise’s Portfolio ALAB Stock Details ALAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-9,300	Closed	-$487K	–	4170
2024 Q3	$487K	Buy	+9,300	New	+$436K	﹤0.01%	3485

Other funds holding ALAB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ameriprise's ALAB Position: Q2 2026 in Review

Ameriprise increased its Astera Labs (ALAB) stake by 35% in Q2 2026, buying an estimated $17.8M and bringing the position to 257,702 shares worth $125M. The position accounts for 0.03% of the portfolio, ranked #520.

Ameriprise first reported a position in ALAB in Q1 2024 and has held it in 10 quarters since. 988 funds tracked by Wall St. Rank hold ALAB as of Q2 2026.

Ameriprise held 257,702 shares of Astera Labs worth $125M as of Q2 2026.
Ameriprise bought 67,082 Astera Labs shares in Q2 2026, an estimated $17.8M.
Astera Labs made up 0.03% of Ameriprise's portfolio in Q2 2026, its #520 holding.
Ameriprise first reported a position in Astera Labs in Q1 2024 and has held it in 10 quarters since.
988 funds tracked by Wall St. Rank held Astera Labs as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.